Thursday, 19 August 2021

CAT grants collective proceedings order application in MasterCard competition law collective proceedings claim

 


 

The Competition Appeal Tribunal (CAT) has given its judgment on the remitted collective proceedings order (CPO) application by Mr Walter Hugh Merricks CBE (Merricks).  This is a milestone judgment certifying the first collective damages action for breach of competition law under the UK’s bespoke collective actions regime.

Merricks sought permission to act as the class representative to bring opt-out collective proceedings under section 47B of the Competition Act 1998 (Competition Act).  The collective proceedings concern follow-on actions for damages arising from the European Commission's 2007 decision finding that MasterCard's EEA multilateral interchange fees breached Article 101(1) TFEU.

The CAT dismissed Merricks’ application for a CPO in July 2017. The Court of Appeal and Supreme Court upheld Merricks' appeal.  The Supreme Court remitted the CPO application to the CAT for reconsideration.

The CAT authorised Merricks as the class representative under section 47B(8) of the Competition Act provided that a suitable undertaking as to liability for adverse costs is given by his litigation funder.

The CAT ruled that the claim for compound interest could not be fairly resolved in collective proceedings.  It considered that compound interest would result in a claim for a “gargantuan amount”.  The CAT expects a plausible methodology to be put forward at this stage, “even if it may need refinement later”.

The CAT also ruled that a claim for damages cannot be brought in the name of a deceased person under section 47B of the Competition Act.  The CAT held that a claim by an individual for loss caused by Mastercard's infringement of competition law will, on their death, vest in their estate.  

The CAT will hear further submissions from the parties as to the domicile date and date for opt-in and opt-out notifications to be set out in the CPO.

Walter Hugh Merricks CBE v Mastercard Incorporated and others [2021] CAT 28

Friday, 6 August 2021

CMA sends statement of objections to Pfizer-Flynn – again

 

CMA sends statement of objections to Pfizer-Flynn – again

 

The Competition and Markets Authority (CMA) has issued a statement of objections in the remittal case concerning abuse of dominance by Pfizer and Flynn for charging unfair prices for phenytoin sodium capsules in the UK.

The Competition Appeal Tribunal held in June 2018 that the CMA had made errors in its conclusions on abuse of dominance and application of the legal test for excessive pricing.  The CAT remitted the case to the CMA insofar as it deals with excessive pricing.

In March 2020 the Court of Appeal dismissed an appeal by Flynn but allowed the CMA’s appeal in part as to excessive pricing.  This did not affect the CAT’s overall conclusions on excessive pricing and the Court affirmed the CAT’s decision on remittal.

The CMA has now issued a statement of objections provisionally finding that the parties abused their respective dominant positions.

For a four year period Pfizer's prices were between 780% and 1,600% higher than it had previously charged.

Pfizer supplied the drug to Flynn, which sold it to wholesalers and pharmacies at prices between 2,300% and 2,600% higher than those they had paid previously.

The statement of objections comes one week after the CMA fined Advanz Pharma in excess of £100 million for excessive pricing of the thyroid medication liothyronine.  The wording in the two press releases is very similar and suggests very similar theories of harm. 

https://www.gov.uk/government/news/cma-accuses-pharma-firms-of-illegal-pricing

Friday, 30 July 2021

CMA fines Advanz Pharma for excessive and unfair pricing

 

CMA fines Advanz Pharma for excessive and unfair pricing

The CMA has imposed penalties of over £100 million on Advanz Pharma for inflating the price of thyroid tablets.

The CMA finds that Advanz increased the price of thyroid tablet packs from £20 in 2009 to £248 in 2017, an increase of 1,110%.

The CMA says that this fine “sends a clear message” to the pharmaceutical sector that infringements of competition law will not be accepted.

The practices at issue were found to be an abuse of a dominant position contrary to the chapter II prohibition.  In 2007, Advanz developed a ‘price optimisation’ strategy whereby it de-branded certain drugs which faced limited generic competition.  In so doing, it could remove them from the price regulation regime which applied to branded drugs, allowing it pricing freedom.

The CMA finds that as a result of the infringements the NHS lost out.  In the year before the infringements were implemented NHS spending was £600,000, but by 2009 this had increased to over £2.3 million and was £30 million by 2016.

This decision is part of the CMA's ongoing work to tackle against anti-competitive practices in the pharmaceutical sector.

 

https://www.gov.uk/government/news/cma-fines-pharma-firm-over-pricing-of-crucial-thyroid-drug

Saturday, 24 July 2021

CMA report in electrical vehicles market study

 

CMA report in electrical vehicles market study

The Competition and Markets Authority (CMA) has published its final report in its market study into the supply of charging for electric vehicles (EVs) in the UK.  The inquiry was launched in December 2020.

The CMA concludes that while some parts of the sector are developing quite well, including venues such as shopping centres, workplaces and private parking, other parts are faring comparatively worse.

This situation could have an impact on the UK’s wider commitment to net zero and the government’s commitments to ban the sale of new petrol and diesel cars, in each case by 2030.

Amongst the CMA’s recommendations are that the government set out a national strategy for rolling out EV charging between now and 2030.

The CMA also recommends that the government attaches conditions to its £950 million Rapid Charging Fund.

Separately, the CMA has also launched a competition investigation into long-term exclusive arrangements between the Electric Highway Company and three motorway service area operators.

The CMA has stated that it will work with government and the devolved administrations with a view to creating an EV sector that people can have trust and confidence in.  Given the importance of EVs, in particular to the achievement of net zero it is likely that this is not the last we have heard about competition in the sector.

https://www.gov.uk/government/news/further-action-needed-on-ev-charging-to-meet-net-zero

 

Wednesday, 21 July 2021

Consultation on new competition regime for digital markets

 


The Departments for Digital, Culture, Media and Sport (DCMS) and Business, Energy and Industrial Strategy (BEIS) have published a joint consultation on a new competition regime for digital markets and the establishment of the Digital Markets Unit (DMU).

The consultation crystallises the ongoing debate about whether we should establish ex ante economic regulation of ‘digital platforms’, with or without ‘enhanced’ competition law – and what form those regulatory frameworks should take place.  This question is a pressing priority for policymakers and competition authorities globally including in the UK, EU and internationally.

The consultation seeks views on: 1) the criteria and mechanisms that will identify which firms fall within the scope of the new regime; . 2)  a new code of conduct to promote open choices, fair trading and trust and transparency; 3) the powers the DMU will have to make pro-competition interventions that will address the root causes of market power; 4) a distinct merger regime for firms with strategic Market Status (SMS), overseen by the Competition and Markets Authority.  To designate a firm with SMS, the DMU will be required to test and conclude that a firm has substantial and entrenched market power in at least one activity, providing it with a strategic position.  There is no broadly accepted regulatory model.  For example, should all platforms meeting certain criteria be regulated in the same way?  

The deadline for responding to the consultation is 1 October 2021.

 

 

https://www.gov.uk/government/consultations/a-new-pro-competition-regime-for-digital-markets

 

Thursday, 15 July 2021

CMA fines for excessive and unfair pricing and market sharing in the supply of hydrocortisone tablets


The Competition and Markets Authority (CMA) has imposed fines totalling over £260 million for competition law violations in relation to the supply of hydrocortisone tablets.

Hydrocortisone is used to treat inflammatory skin conditions as well as Addison’s Disease, a rare adrenal glands disorder.

The CMA found that Auden Mckenzie and Actavis UK (now “Accord UK”) imposed on the NHS “excessive and unfair” prices for hydrocortisone tablets from 2008 to 2018.

The CMA further found that the companies paid generic suppliers to keep their rival products out of the UK market. It appears that this so called “pay for delay” element of the case was a significant factor in the high prices. The CMA states that the NHS was at one point being charged over £80 for a single pack of tablets that had previously cost less than £1.

The decision represents the most significant and authoritative UK competition case to date on excessive pricing (at least until there is a new decision in the Pfizer/Flynn case). This has traditionally been one of the more difficult areas of competition law infringement to establish. The case comes as a warning shot that the CMA will not shy away from bringing a competition case in respect of excess pricing where it believes that consumers (here, the NHS and the taxpayer) are paying over the odds because the market is deprived from new (generic) entry.

https://www.gov.uk/government/news/cma-finds-drug-companies-overcharged-nhs


#pharmacompetition

Thursday, 8 July 2021

Commission fines car manufacturers €875 million for restricting competition in emission cleaning

 

Commission fines car manufacturers €875 million for restricting competition in emission cleaning

The European Commission has found that Daimler, BMW and Volkswagen group (Volkswagen, Audi and Porsche) violated EU competition law by colluding on technical development in the area of nitrogen oxide cleaning.

The Commission imposed penalties of €875,189,000.

Daimler avoided a fine which would have amounted to around €727 million..  As the leniency applicant it revealed the existence of the cartel to the Commission.  

The Commission applied a reduction of 10% of the fines of all parties under the 2008 Settlement Notice in view of the acknowledgment of their participation in the cartel.

The Commission found that the parties colluded from June 2009 to October 2014 by indicating to each other that none of them would aim above the minimum standards required by law.  Interestingly the Commission abandoned some of its earlier allegations where it found insufficient evidence to substantiate them.  The Commission did not pursue that part of its case that the collusion also affected petrol cars.

The decision is aligned with the Commission’s Green Deal agenda even if it is not presented as such. However this does not mean that all cooperation on green technical development is a hardcore infringement and the Commission will need to provide guidance so as to distinguish what is flagrantly anti-competitive and what might be pro-competitive on a balancing of the benefits and risks to competition.

https://ec.europa.eu/commission/presscorner/detail/en/ip_21_3581